Why Myovant Sciences Stock Is Up Triple Digits Today
Shares of Myovant Sciences (NYSE: MYOV) are skyrocketing today, up 161% as of 10:45 a.m. EST, after the clinical-stage biotech released results from its phase 3 HERO study.
The HERO study was designed to test the safety and efficacy of Myovant's lead compound, relugolix, as a hopeful treatment for men with androgen-sensitive advanced prostate cancer who required at least one year of continuous androgen deprivation therapy. The trial pitted relugolix against the current standard-of-care treatment leuprolide acetate.
Here are the key takeaways from the study:
Source Fool.com
